Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study

Modern Rheumatology

Volumn 26, Issue 1, 2016, Pages 24-28

  Yonemoto, Yukio ^a   Okamura, Koichi ^a   Takeuchi, Kimihiko ^b   Ayabe, Keio ^c   Kaneko, Tetsuya ^d   Matsushita, Masatoshi ^b   Tamura, Yasuyuki ^d   Iso, Takenobu ^e   Okura, Chisa ^a   Otsuka, Keiko ^b   Inoue, Hiroshi ^d   Takagishi, Kenji ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Isesaki Fukushima Hospital   (Japan)

^c Keiyu Orthopaedic Hospital   (Japan)

^d Inoue Hospital   (Japan)

^e Gunma Rheumatism Clinic   (Japan)

Author keywords

Biologics; Golimumab; Monotherapy; Multicenter cohort study; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; GOLIMUMAB; METHOTREXATE; MUCIN 1; STROMELYSIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; STOMACH ULCER; THROMBOCYTE DISORDER; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952874001     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1069472     Document Type: Article

References (27)

1. Singh J A, Furst D E, Bharat A , Curtis J R, Kavanaugh A F, Kremer J M, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 ; 64(5) : 625-39. doi: 10.1002/acr.21641.
2. Smolen JS , Landewé R , Breedveld FC , Buch M , Burmester G , Dougados M , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 ; 73(3) : 492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.
3. Smolen JS , Aletaha D , Bijlsma JW , Breedveld FC , Boumpas D , Burmester G , et al.; for the T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010; 69(4): 631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9.
4. Lipsky PE , van der Heijde DM , St Clair EW , Furst DE , Breedveld FC , Kalden JR, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (IFX XP). Infl iximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22): 1594-602.
5. Maini RN , Breedveld FC , Kalden JR , Smolen JS , Furst D , Weisman MH , et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (IFX HAQ). Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infl iximab and methotrexate. Arthritis Rheum. 2004 ; 50(4) : 1051-65.
6. Klareskog L , van der Heijde D , de Jager J P, Gough A , Kalden J , Malaise M, et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic eff ect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Doubleblind randomised controlled trial. Lancet. 2004 ; 363(9410) : 675-81.
7. Favalli EG, Biggioggero M , Meroni P L. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an " anchor " drug? Autoimmun Rev. 2014 ; 13(11) : 1102-8. doi: 10.1016/j.autrev.2014. 08.026. Epub 2014 Aug 26.
8. Breedveld FC , Weisman MH , Kavanaugh AF , Cohen SB , Pavelka K , van Vollenhoven R , et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab-methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 ; 54(1) : 26-37.
9. Emery P , Fleischmann RM , Moreland LW , Hsia EC , Strusberg I , Durez P , et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twentyfour-week results of a phase III, multicenter, randomized, doubleblind, placebo-controlled study of golimumab before methotrexate as fi rst-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009 ; 60(8) : 2272-83. doi: 10.1002/art.24638.
10. Kay J , Matteson EL , Dasgupta B , Nash P , Durez P , Hall S , et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebocontrolled, dose-ranging study. Arthritis Rheum. 2008 ; 58(4) : 964-75. doi: 10.1002/art.23383.
11. Kremer J , Ritchlin C , Mendelsohn A , Baker D , Kim L , Xu Z , et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week effi cacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010 ; 62(4) : 917-28. doi: 10.1002/art.27348.
12. Keystone E C, Genovese M C, Klareskog L , Hsia E C, Hall S T, Miranda PC , et al.; GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis. 2009 ; 68(6) : 789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9.
13. Keystone E , Genovese M C, Klareskog L , Hsia E C, Hall S , Miranda P C, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010 ; 69(6) : 1129-35. doi: 10.1136/ard.2009.116319. Epub 2010 May 5.
14. Tanaka Y , Harigai M , Takeuchi T , Yamanaka H , Ishiguro N , Yamamoto K, et al.; GO-FORTH Study Group. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: Results of the GO-FORTH study. Ann Rheum Dis. 2012; 71(6): 817-24. doi: 10.1136/ard.2011.200317. Epub 2011 Nov 25.
15. Takeuchi T , Harigai M , Tanaka Y , Yamanaka H , Ishiguro N , Yamamoto K , et al.; GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: Results of the phase 2/3, multicentre, randomised, double-blind, placebocontrolled GO-MONO study through 24 weeks. Ann Rheum Dis. 2013 ; 72(9) : 1488-95. doi: 10.1136/annrheumdis-2012-201796. Epub 2012 Sep 14.
16. Aletaha D , Neogi T , Silman A J, Funovits J , Felson D T, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classifi cation criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 ; 62(9) : 2569-81. doi: 10.1002/art.27584.
17. DAS-SCORE.NL. http://www.das-score.nl/, the Netherlands.
18. Aletaha D , Smolen J. The Simplifi ed Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005 ; 23(5 Suppl 39) : S100-8.
19. Smolen J S, Breedveld F C, Schiff MH , Kalden JR , Emery P , Eberl G , et al. A simplifi ed disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003; 42(2): 244-57.
20. Mallinckrodt CH , Sanger TM , Dubé S , DeBrota DJ , Molenberghs G, Carroll RJ, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003 ; 53(8) : 754-60.
21. Sato E , Tanaka E , Nakajima A , Inoue E , Shimizu Y , Yamaguchi R , et al. Assessment of the eff ectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. Mod Rheumatol. 2015 ; 9 : 1-6. [Epub ahead of print].
22. Kanbe K , Chiba J , Inoue Y , Taguchi M , Yabuki A. Predictive factors related to the effi cacy of golimumab in patients with rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2015 ; 8 : 25-32. doi: 10.4137/CMAMD.S22155. eCollection 2015.
23. Schoels M , Aletaha D , Smolen J S, Wong J B. Comparative eff ectiveness and safety of biological treatment options after tumour necrosis factor ?inhibitor failure in rheumatoid arthritis: Systematic review and indirect pairwise meta-analysis. Ann Rheum Dis. 2012; 71(8): 1303-8. doi: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30.
24. Smolen J S, Kay J , Doyle M K, Landewé R , Matteson E L, Wollenhaupt J, et al.; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, doubleblind, placebo-controlled, phase III trial. Lancet. 2009; 374(9685): 210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26.
25. Mancarella L , Bobbio-Pallavicini F , Ceccarelli F , Falappone P C, Ferrante A, Malesci DJ , et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: The GISEA study. Rheumatol. 2007 ; 34(8) : 1670-3. Epub 2007 Jul 1.
26. Burmester G R, Ferraccioli G , Flipo R M, Monteagudo-Sáez I , Unnebrink K , Kary S , Kupper H. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 2008 ; 59(1) : 32-41. doi: 10.1002/art.23247.
27. van der Heijde D , Klareskog L , Landewé R , Bruyn G A, Cantagrel A , Durez P , et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 56(12): 3928-39.